en · de · es · fr · pt
glossary-desk.peptides6155.com › Data › Tb-500 Background And Identity — 2026 Update

Tb-500 Background And Identity — 2026 Update

By Editorial Desk · published 2025-08-14 · last reviewed 2025-09-22 · Data

The short version of reverse-phase HPLC fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2025-09-22 and is reviewed periodically as new material appears.

TB-500 Background and Identity

TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.

The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.

Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.

Identity And Naming Background

TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.

Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.

Tb-500 at a glance

PropertyValueNotes
AppearanceWhite to off-white lyophilized powderTypical form for short synthetic peptides
Solubility classFreely soluble in water and aqueous bufferDissolution aided by gentle mixing, not vigorous shaking
Typical storage temperature−20 °C, desiccated−80 °C used for long-term holding
Common analytical methodReverse-phase HPLC with UV detection near 214 nmIdentity confirmed separately by mass spectrometry
Common synonymsThymosin beta-4 fragment; TB4 fragmentNaming varies between suppliers and publications

Handling, Storage, and Analytical Verification

The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.

Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.

Related pages on this site

Thymosin Beta-4 Fragment Overview

Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.

The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.

Handling, Stability and Analytical Detection

Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.

Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.

Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.

Supporting material

=== Early work in comedy and television === Morgan made his screen debut playing Hustle Man on the sitcom Martin. The character sold various items from the "hood", always greeting people with his signature "What's happ'n, chief?," and had a pet dog he dressed as a rapper. (Later, in the 2003 Chris Rock film Head of State, Morgan appeared as a man watching television, often questioning why they are not watching Martin.) Morgan was also a regular cast member on Uptown Comedy Club, a sketch-comedy show filmed in Harlem that aired for two seasons, from 1992 to 1994. Morgan joined the cast of the comedy series Saturday Night Live in 1996, and performed as a regular until 2003. Producer Lorne Michaels chose him over Stephen Colbert in the final round of auditions. Morgan's regular characters included the kindly but deluded vagrant Woodrow; outspoken apartment maintenance man Dominican Lou; lusty Astronaut Jones whose short skits ended with blunt sexual propositions towards beautiful extraterrestrial ladies; and Safari Planet host Brian Fellow who was enthusiastic but deeply ignorant about animals.

=== Food === Fumaric acid has been used as a food acidulant since 1946. It is approved for use as a food additive in the EU, USA, Australia, and New Zealand. As a food additive, it is used as an acidity regulator and can be denoted by the E number E297. It is generally used in beverages and baking powders for which requirements are placed on purity. Fumaric acid is used in the making of wheat tortillas as a food preservative and as the acid in leavening. It is generally used as a substitute for tartaric acid and occasionally in place of citric acid, at a rate of 1 g of fumaric acid to every ~1.5 g of citric acid, in order to add sourness, similarly to the way malic acid is used. As well as being a component of some artificial vinegar flavors, such as "Salt and Vinegar" flavored potato chips, it is also used as a coagulant in stove-top pudding mixes. The European Commission Scientific Committee on Animal Nutrition, part of DG Health, found in 2014 that fumaric acid is "practically non-toxic" but high doses are likely nephrotoxic after long-term use.

==== Sublabial ==== Sublabial administration is achieved by placing the drug between the lip and gum. The frenulum of the tongue may be irritated when in contact with corrosive materials but can be avoided with this route. It is usually used for medications such as nitroglycerin, for example.

Sources: en.wikipedia.org

Notes from published material

== Further reading == Bernard, MA; Valli, VE (1977). "Familial renal disease in Samoyed dogs". The Canadian Veterinary Journal. 18 (7): 181–9. PMC 1697612. PMID 884645. Meyers, VN; Jezyk, PF; Aguirre, GD; Patterson, DF (1983). "Short-limbed dwarfism and ocular defects in the Samoyed dog". Journal of the American Veterinary Medical Association. 183 (9): 975–9. doi:10.2460/javma.1983.183.09.975. PMID 12002589. S2CID 32585084. Kimmel, SE; Ward, CR; Henthorn, PS; Hess, RS (2002). "Familial insulin-dependent diabetes mellitus in Samoyed dogs". Journal of the American Animal Hospital Association. 38 (3): 235–8. doi:10.5326/0380235. PMID 12022409.

== Pathophysiology == Overproduction of collagen is thought to result from an autoimmune dysfunction, in which the immune system starts to attack the kinetochore of the chromosomes. This would lead to genetic malfunction of nearby genes. T cells accumulate in the skin; these are thought to secrete cytokines and other proteins that stimulate collagen deposition. Stimulation of the fibroblast, in particular, seems to be crucial to the disease process, and studies have converged on the potential factors that produce this effect.

== Development == The game was originally created and released by Daniel Fearon. At the time, Fearon was one of the maintainers of the Half-Life fan website Atomic Half-Life, created in anticipation of the game's release. Fearon was sent a copy of Half-Life by Valve prior to its official release, and while playing it, he toyed with the game's code, figuring out how to spawn enemy creatures in multiplayer maps. Fearon's work had initially been done before Valve released the software development kit for Half-Life, requiring him to craft the modification atop the existing Half-Life distribution and to work with multiplayer over slower internet connections, such as phone-line modems. Fearon initially developed a single map that could be played cooperatively, and later a second version with two maps. The first public version of Sven Co-op was released on January 19, 1999, about 3 months after the release of Half-Life. He used the name Sven Co-op to reflect his online handle, "Sven Viking". Contrary to the common belief that Sven Co-op was developed to play through Half-Life cooperatively, Fearon had wanted to create a means for players to engage in cooperative experiences together, often just spawning in large number of enemies for them to dispatch together on a single map. This drew a number of amateur level developers to craft mission-based maps for the mod, where players would be required to go to different areas on the map based on success or failure of a given objective.

Sources: en.wikipedia.org

Further detail

Macrophages are professional phagocytes and are highly specialized in removal of dying or dead cells and cellular debris. This role is important in chronic inflammation, as the early stages of inflammation are dominated by neutrophils, which expend themselves and are ingested by macrophages. Macrophages normally present themselves at the wound site within 2 days following the injury. The neutrophils are at first attracted to a site, where they perform their function and die, before they or their neutrophil extracellular traps are phagocytized by the macrophages. The first wave of neutrophils acts for approximately 2 days at the site and signals to attract macrophages. These macrophages will then ingest the aged neutrophils. The removal of dying cells is, to a greater extent, handled by fixed macrophages, which will stay at strategic locations such as the lungs, liver, neural tissue, bone, spleen and connective tissue, ingesting foreign materials such as pathogens and recruiting additional macrophages if needed. The phagocytosis and clearance of apoptotic remains is called efferocytosis and is also carried out by other cell types, not all of which are professional phagocytes. When a macrophage ingests a pathogen, the pathogen becomes trapped in a phagosome, which then fuses with a lysosome. Within the phagolysosome, enzymes and toxic peroxides digest the pathogen. However, some bacteria (such as Mycobacterium tuberculosis) have become resistant to these methods of digestion.

The black mamba (Dendroaspis polylepis) is a large and highly venomous snake species native to much of Sub-Saharan Africa. It is the second-longest venomous snake species in the world and is the fastest-moving land snake, capable of moving at 4.3 to 5.4 metres per second (16–20 km/h, 10–12 mph). The black mamba is the most feared snake in Africa because of its size, aggression, venom toxicity and speed of onset of symptoms following envenomation, and is classified as a snake of medical importance by the World Health Organization. This species of snake shows tenacity, fearlessness, and aggression when cornered or threatened, during breeding season, or when defending its territory. They are also known to have up to a 100% rate of envenomation; the probability of dry bites (no venom injected) in black mamba strikes is almost non-existent. The venom of the black mamba is a protein of low molecular weight and as a result is able to spread rapidly within the bitten tissue. The venom is the most rapid-acting venom of any snake species and consists mainly of highly potent neurotoxins; it also contains cardiotoxins, fasciculins, and calciseptine. Based on the median lethal dose (LD50) values in mice, the black mamba LD50 from all published sources is as follows:

== Background == Following his victory at the Battle of Pelagonia in 1259 AD against an anti-Nicaean coalition, Nicaean emperor Michael VIII Palaiologos was left free to pursue the reconquest of Constantinople, a primary goal of the Byzantine rump states in both Epirus and Asia Minor since 1204. By 1259 the remnants of the Latin Empire were reduced to the city of Constantinople and its immediate environs, cut off from both the remaining Latin states of Greece and from the Nicaeans' Greek rival, the Despotate of Epirus. As early as 1260, Michael Palaiologos attacked Constantinople, as one of the Latin knights taken prisoner in Pelagonia, whose house was within the city walls, had promised to open a gate for the emperor's troops. He failed to do so, and Palaiologos launched an unsuccessful assault on Galata instead. To strengthen his position, Michael concluded an alliance with Genoa in March 1261. In July 1261, as the one-year truce agreed upon after the failed Nicaean siege of 1260 was nearing its end, the general Alexios Strategopoulos was sent with a small advance force of 800 soldiers (most of them Cumans) to keep a watch on the Bulgarians and to reconnoiter the Latin defenses of the city.

The contamination in the Ganga-Brahmaputra fluvial plains in India and Padma-Meghna fluvial plains in Bangladesh demonstrated adverse impacts on human health. Clare Luce, American ambassador to Italy from 1953 to 1956, suffered from arsenic poisoning. Its source was traced to flaking arsenic-laden paint on the ceiling of her bedroom. She may also have eaten food contaminated by arsenic in flaking ceiling paint in the embassy dining room. Arsenic poisoning from exposure to groundwater is believed to be responsible for the illness experienced by those that witnessed the 2007 Carancas impact event in Peru, as local residents inhaled steam which was contaminated with arsenic, produced from groundwater which boiled from the intense heat and pressure produced by a chondrite meteorite impacting the ground. Ground water contaminated by arsenic, as of 2014, "is still poisoning millions of people in Asia".

Sources: en.wikipedia.org

Frequently asked questions

What is TB-500?

TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.

Is TB-500 identical to thymosin beta-4?

Not necessarily. Some vendors use the name for the full 43-residue protein, while others apply it to a short actin-binding fragment or to a related tetrapeptide. The sequence should be confirmed from documentation rather than assumed from the label.

Is TB-500 an approved medicine?

No thymosin beta-4 fragment holds marketing approval as a medicine in major jurisdictions. Material offered for sale is typically labelled for laboratory research only.

Is TB-500 identical to thymosin beta-4?

No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.

Network